<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02439333</url>
  </required_header>
  <id_info>
    <org_study_id>2015-KE-63</org_study_id>
    <nct_id>NCT02439333</nct_id>
  </id_info>
  <brief_title>Prospective Randomized Study of Nasal High Flow in Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Li Xuyan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main oxygen therapy to the patients with acute exacerbation of Chronic obstructive
      pulmonary disease, who are mild to moderate respiratory insufficiency (arterial blood gas
      analysis showed pH = 7.35, PO2 &lt; 60mmHg,PaCO2＞45mmHg) or have achieved the traditional
      noninvasive ventilation support standard but can not tolerate or reject, was nasal catheter,
      venturi mask and other conventional oxygen therapy. All these inaccurate inhaled oxygen
      concentration methods with inadequate heating and humidifying lead to poor patient tolerance
      and adverse reactions such as airway secretions discharge disorders. The high flow nasal
      respiratory therapy (Nasal high flow, NHF) utilises higher gas flow rates than conventional
      low-flow oxygen systems. The devices used deliver heated and humidified oxygen at a flow of
      up to 60 litres per minute via nasal cannulas with low level continous positive airway
      pressure. This study is a prospective randomized study. AECOPD patients with no severe
      respiratory failure are treated with NHF and conventional oxygen therapy respectively. The
      target is that NHF can increase the comfort degree of patients,reduce the rate of
      endotracheal intubation, and shorten the time of hospitalization.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure criteria</measure>
    <time_frame>5 days</time_frame>
    <description>Patients with mild respiratory acidosis (7.25 &lt; pH &lt; 7.35) with obvious dyspnea (accessory respiratory muscle involvement, breathing rate greater than 25 beats per minute)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs of hospitalization expenses</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Lung Diseases, Obstructive</condition>
  <arm_group>
    <arm_group_label>Nasal high flow therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AECOPD patients with no severe respiratory insufficiency are given NHF therapy for at least 15 hours per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional oxygen therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AECOPD patients with no severe respiratory insufficiency are given conventional oxygen therapy such as nasal catheter or venturi mask for at least 15 hours per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nasal high flow cannula (Fisher &amp; Paykel Healthcare, Auckland, New Zealand)</intervention_name>
    <description>Nasal high flow therapy</description>
    <arm_group_label>Nasal high flow therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nasal catheter or Venturi mask</intervention_name>
    <description>Conventional oxygen therapy</description>
    <arm_group_label>Conventional oxygen therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AECOPD patients.

          -  The results of blood gas analysis showed pH ≥7.35, PO2＜ 60mmHg, PaCO2＞ 45mmHg.

        Exclusion Criteria:

          -  The study case has been incorporated into the hospital again.

          -  Refused to the NHF therapy.

          -  The Glasgow score &lt; 8.

          -  Severe organ dysfunction (including liver and kidney dysfunction, decompensated
             acidosis, upper gastrointestinal bleeding, DIC, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bing Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuyan Li, MD</last_name>
    <phone>0086-10-85231543</phone>
    <email>araklee@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bing Sun, MD</last_name>
    <phone>86013911151075</phone>
    <email>ricusunbing@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of respiratory and critical care medicine,Beijing Chao-yang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuyan Li, MD</last_name>
      <phone>0086-10-85231543</phone>
      <email>araklee@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Bing Sun, MD</last_name>
      <phone>86013911151075</phone>
      <email>ricusunbing@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2015</study_first_submitted>
  <study_first_submitted_qc>May 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Li Xuyan</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Acute exacerbation of chronic obstructive pulmonary disease</keyword>
  <keyword>Nasal high flow therapy</keyword>
  <keyword>Oxygen therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

